35 results
6-K
EX-99.1
CALT
Calliditas Therapeutics AB
25 Apr 24
Current report (foreign)
4:06pm
. In IgAN patients, a combi-nation of a genetic predisposition and of environmental, bacterial and dietary factors is presumed to lead to an increased … ’ sustainability impact is in seven main areas, which in turn are divided based on whether the impact is related to environmental, social or governance
6-K
EX-99.2
CALT
Calliditas Therapeutics AB
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
-deficient. In IgAN patients, a combination of a genetic predisposition and environmental, bacterial and dietary factors is presumed to lead … acquainted with its most important sustainability matters from an environmental, social and corporate perspective. The assessment was performed
6-K
EX-99.1
5wuu5xgj n14nyg
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
EX-99.1
olg 1vdju
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
6-K
EX-99.1
48ze rph17gp
16 May 23
Current report (foreign)
4:05pm
6-K
EX-99.1
7qps8 vgx8a2y1ry6px
28 Apr 23
Current report (foreign)
4:05pm
6-K
EX-99.1
qkj9ams4ngr7zi kdhga
14 Nov 22
Current report (foreign)
5:25pm
6-K
EX-99.1
psz9n4n
19 Aug 22
Interim Report January 1ST – June 30TH 2022
7:55am
F-3
EX-1.2
7jrsz
28 Jun 22
Shelf registration (foreign)
4:49pm
6-K
EX-99.1
9o9 jbq07
20 May 22
Interim Report January 1ST – March 31ST 2022
4:34pm
6-K
EX-99.1
j37jkzdnd556qibqjydr
29 Apr 22
Current report (foreign)
4:02pm
6-K
EX-99.2
jjdtx7crmirlr
24 Feb 22
Current report (foreign)
4:05pm
6-K
EX-99.1
19gh8ht n381q
20 Aug 21
Current report (foreign)
5:28pm
6-K
EX-10.1
uqb148 jg98r9r
23 Jul 21
Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe
4:03pm
6-K
EX-99.2
ri4th79y9j4rzkfgs 2f
18 May 21
Filing of New Drug Application submission to the FDA
9:00am